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Purpose: To examine the variation in venous thromboembolism prophylactic treatment (VTEP) 
among renal cancer patients undergoing surgery.
Materials and methods: An Internet-based questionnaire on renal tumor management before 
and after surgery was mailed to all Nordic departments of urology. The questions focused on 
the use of VTEP and were subdivided into different surgical modalities.
Results: Questionnaires were mailed to 91 institutions (response rate 53%). None of the cen-
ters used VTEP before surgery, unless the patient had a vena caval tumor thrombus. Overall, 
the VTEP utilized during hospitalization for patients undergoing renal surgery included early 
mobilization (45%), compression stockings (52%) and low-molecular-weight heparin (89%). 
In patients undergoing open radical Nx, 80% of institutions used VTEP during their hospital-
ization (23% compression stockings and 94% low-molecular-weight heparin). After leaving 
the hospital, the proportion and type of VTEP received varied considerably across institutions. 
The most common interval, used in 60% of the institutions, was for a period of 4 weeks. The 
restriction to the Nordic countries was a limitation and, therefore, may not reflect the practice 
patterns elsewhere. It is a survey study and, therefore, cannot measure the behaviors of those 
institutions that did not participate.
Conclusion: We found variation in the type and duration of VTEP use for each type of local 
intervention for renal cancer. These widely disparate variations in care strongly argue for the 
establishment of national and international guidelines regarding VTEP in renal surgery.
Keywords: venous-thrombotic-embolic prophylaxis kidney cancer, surgery, nephrectomy, 
mortality, complication, minimally invasive methods, thrombosis prophylaxis
Introduction
The development of venous thromboembolism (VTE) is due to an imbalance in hema-
tostasis, which in Virchow’s triad is described as an interaction between the vessel wall, 
blood flow and blood composition.1 Prolonged immobilization or direct compression 
of the veins from a growing kidney tumor can give reduced flow in cancer patients and 
are well-known risk factors for VTE. Cancerous diseases can result in both direct and 
indirect effects on the vessel wall due to tumor invasion or increased inflammatory 
influence affecting both the vessel walls and the components of the coagulation cascade.
Cancer surgery is associated with a doubling of the risk of postoperative VTE 
compared with similar surgery for benign diseases.2 Patients with pancreatic or gastric 
cancer have the greatest risk, while pulmonary, bladder and gynecological cancers also 
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have an increased risk.3 In a prospective cohort study, VTE 
was the most frequent cause of death within the first 30 days 
after cancer surgery for a variety of different malignancies 
and 40% of postoperative VTE occurred at least 21 days after 
surgical intervention.4 A high dose of low-molecular-weight 
heparin (LMWH; 5,000 vs 2,500 IU) results in significantly 
lower incidence of VTE in cancer surgery without an 
increased bleeding risk.5 A Cochrane review concluded that 
4 weeks of thrombosis prophylaxis after major abdominal 
and pelvic surgery reduces the risk of postoperative VTE.6
The five Nordic countries (Denmark, Finland, Iceland, 
Norway and Sweden) comprise 25 million people, and have 
quite similar treatment traditions and state-funded high-
quality health care systems.
The Nordic Renal Cancer group is a newly formed work-
ing group with representatives from all the Nordic countries, 
with the aim of performing high-quality research on kidney 
cancer in the Nordic countries.7 The purpose of this study 
is to examine the use of VT prophylactic treatment (VTEP) 
among renal cancer patients undergoing curative therapy in 
the five Nordic countries prior to the publishing of the first 
European Association of Urology (EAU) Guidelines on 
thromboprophylaxis in urological surgery.8
Materials and methods
The study group
The study was carried out by a collaborative group originat-
ing from the Scandinavian Association of Urology and is 
presented at the homepage of the Scandinavian Association 
of Urology (www.NUF.nu).
The questionnaire
A 21-question Internet-based questionnaire on renal tumor 
management before and after surgery was mailed to all 
Nordic departments of urology performing renal cancer 
surgery (Supplementary material). The questions addressed 
the use of VTEP and were subdivided into different surgi-
cal modalities: open radical and partial nephrectomy (Nx), 
laparoscopic/robotic Nx and laparoscopic and percutaneous 
thermal ablation of tumors.
In total, 91 institutions from all five countries were 
invited to participate. The questionnaires were mailed to the 
departments during late fall of 2016, and after two rounds 
of invitations, the database was closed on February 1, 2017. 
Six institutions did not perform renal surgery in 2016. We 
received responses from 45 of 85 hospitals performing 
any form of renal surgery (response rate 53%), as shown 
in Table 1. There were responses from 6 institutions from 
Denmark (75%), 12 from Finland (48%), 1 from Iceland 
(100%), 11 from Norway (73%) and 15 from Sweden (48%), 
as shown in Table 1.
The survey did not include patient-related data or 
affected patient treatment or care. Therefore, it did not 
require approval from the ethical committee. Completion 
of the survey was considered as informed consent from the 
participating departments.
Results
None of the 45 institutions used VTEP before surgery unless 
the patient had a vena caval tumor thrombus. Overall, the 
proportion of institutions that used VTEP during hospital-
ization for patients undergoing renal surgery included 45% 
using early mobilization, 52% using compression stockings 
and 89% using LMWH (Table 2). In patients undergoing 
open radical Nx, 80% of the institutions used VTEP during 
their hospitalization (23% compression stockings and 94% 
LMWH; Table 3). After leaving the hospital, the propor-
tion and type of VTEP received varied considerably across 
institutions (5% for 1 week, 35% for 2 weeks and 60% for 
4 weeks). For patients undergoing open partial Nx, 75% of 
institutions utilized VTEP (27% compression stockings and 
91% LMWH; Table 3). After discharge, the VTEP regimen 
offered to patients was for 1 week in 12%, 2 weeks in 48% 
and 4 weeks in 40% of the institutions. For patients undergo-
ing robotic radical Nx, 73% of the institutions utilized VTEP 
(27% compression stockings and 85% LMWH; Table 3). 
After hospital discharge, VTEP duration across institutions 
was 15% for 1 week, 39% for 2 weeks, 36% for 4 weeks and 
10% for other. For those who underwent laparoscopic/robotic 
partial Nx, 70% of the institutions utilized VTEP (29% 
compression stockings and 85% LMWH; Table 3). VTEP 
was continued after discharge from the hospital for 1 week, 2 
weeks and 4 weeks in 20%, 48% and 32% of the institutions, 
Table 1 The response rate from the different nordic countries 
among the institutions which perform therapeutic procedures for 
renal cancer






Finland 25 12 48
norway 15 11 73
sweden 36 15 42
Denmark 8 6 75
iceland 1 1 100
Total 85 45 53
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respectively. Five centers performed laparoscopic/robotic 
thermal ablation of tumors, and overall, 60% used compres-
sion stockings and 80% used LMWH. Two centers continued 
VTEP for 1 week (40%) and three centers continued it for 2 
weeks (60%). Three centers performed percutaneous ablation 
and used VTEP using compression stockings (67%) and 33% 
used LMWM. After discharge, one facility continued VTEP 
for 1 week, while the others continued it for 2 weeks. The 
responses for individual questions among institutions from 
the different Nordic countries are shown in Table 2.
Table 2 Tabulated data on what form(s) of VTeP is used by patients undergoing renal surgery while they are in the hospital and after 
they leave the hospital
VTEP when hospitalized Finland (n=12) Norway (n=11) Sweden (n=15) Denmark (n=6) Iceland (n=1)
early ambulation 45% 40% 43% 60% –
compression stockings – 40% 36% 60% –
low-molecular-weight heparin 91% 100% 85% 60% 100%
Abbreviation: VTeP, venous thromboembolism prophylaxis.











Use of VTeP after open 
nephrectomy
Yes 100% 60% 100% 40% 100%
no – 40% – 60% –
Type of VTeP after open 
nephrectomy
compression stockings 18% 33% 14% 100% –
lMWh 100% 100% 93% 100% 100%
Use of VTeP after open partial 
nephrectomy
Yes 91% 60% 100% 40% –
no 9% 40% – 60% 100%
Type of VTeP after open 
partial nephrectomy
compression stockings 20% 33% 14% 100% 100%
subcutaneous heparin – – – 100% –
lMWh 100% 100% 86% 50% –
Use of VTeP after 
laparoscopic/robot-assisted 
nephrectomy
Yes 91% 60% 86% 60% –
no 9% 40% 14% 40% 100%
Type of VTeP after 
laparoscopic/robot-assisted 
nephrectomy
compression stockings 20% 33% 15% 100% –
subcutaneous heparin – – – 67% –
lMWh 100% 100% 69% – –
Unfractionated heparin – – 8% 67% –
Use of VTeP after 
laparoscopic/robot-assisted 
partial nephrectomy
Yes 90% 60% 86% 40% –
no 10% 40% 14% 60% 100%
Type of VTeP after 
laparoscopic/robot-assisted 
partial nephrectomy
compression stockings 100% 33% 15% 50% –





– – 8% 100% –
lMWh – 100% 85% 50% –
Abbreviations: VTeP, venous thromboembolism prophylaxis; lMWh, low-molecular-weight heparin.
Discussion
Our survey results demonstrate wide variability in the 
type, duration and setting for VTEP among institutions 
performing therapeutic surgery/procedures for renal can-
cer in the Nordic countries. As just one example, the use 
of any VTEP after minimally invasive radical Nx ranged 
from 0% to 91% by the institutions within a given country 
(60%–91%, if the one institution that responded from Ice-
land was excluded). For minimally invasive partial Nx, the 
range was 40%–90%. Similar wide variability is seen in 





the type of VTEP utilized and in the duration of VTEP use 
after discharge from the hospital. This is despite the fact 
that both the EAU and Danish Society for Hematostasis 
and Thrombosis recommend that all patients undergoing 
surgery for malignant solid tumors should have thrombosis 
prophylaxis, and that it ought to be given for up to 4 weeks 
after a major surgery.6,8
The variability in practice may reflect critical gaps in our 
knowledge on the use of VTEP in kidney cancer. Perhaps the 
most immediate and glaring gap is the prospective clinical trials 
on VTEP among patients undergoing surgery for renal cancer. 
Several studies have used the American College of Surgeons 
National Surgical Quality Improvement Program to estimate 
the rate of VTE within 30 days after renal cancer surgery and 
found rates between 0.7% and 1.7% (open radical Nx 1.7%, 
laparoscopic radical or partial Nx 0.7%).9–13 While several 
publications have explored the risk factors for the development 
of VTE,9,11,13–15 there are no prospective, randomized trials 
comparing different types, duration and therapeutic settings 
for VTEP among renal cancer surgery patients. A single-center, 
retrospective experience suggested that perioperative use of 
pharmacologic VTEP limited to postoperative hospitalization 
was not associated with lower VTE rates after robotic partial 
nephrectomy.15 However, in this study no investigations were 
done to find out whether the patients received any VTEP pro-
fylaxsis after discharge from the hospital. Further, the study 
is based on a survey and has the potential to suffer from bias.
Another significant gap is the lack of specific guidelines 
for VTEP in urologic surgery. The American Urologic Asso-
ciation and the International Consultation on Urological 
Disease produced a collaborative review, Anticoagulation and 
Antiplatelet Therapy in Urologic Practice, which predomi-
nantly focused on the management of patients on chronic 
anticoagulation or antiplatelet therapy for differing medical 
comorbidities who required a urologic intervention. While 
there have been several review papers on the subject of VTEP 
in urology,16,17 urologic surgery-specific guidelines are largely 
lacking and where guidance exists, it is generally predicated 
on indirect evidence from other surgical procedures rather 
than procedure-specific studies within the urologic literature. 
For example, the EAU has created a guideline on VTEP 
(http://uroweb.org/guideline/thromboprophylaxis/#3) in 
which the quality and indirect nature of the evidence available 
to the panel meant that the overwhelming majority of recom-
mendations were with low or very low quality of evidence 
and most of the recommendations had to be “weak”. This 
is not a reflection on the quality of the guideline per se, but 
on the quality of the evidence available in the literature that 
underlies the guideline process itself.
It is not surprising that given the gaps in evidence and spe-
cific guidance surrounding VTEP for urologic surgery, there 
have been large variations in the use of VTEP reported both 
for radical cystectomy16,18,19 and radical prostatectomy.16,18–20 
Our study is the first report to survey the use of VTEP across 
institutions focused on surgery for renal tumors. As is the 
case with pelvic malignancies, there is widespread variation 
in the use of VTEP in terms of the type used, the surgical 
indications, whether it was used after hospital discharge and 
the total duration after surgery. The significant variability of 
VTEP across most urologic cancer surgery clearly highlights 
the need for urologic-specific VTEP guidelines such as the 
most recent one published by the EAU. Dissemination of 
these guidelines and more widespread adoption should help 
to reduce these variations in care and align practice patterns 
with the evidence available. There are several limitations 
of this study that should be acknowledged. This is a survey 
study and, therefore, cannot measure the behaviors of those 
institutions that did not fill out the instrument. However, the 
overall return rate, 53%, among those institutions perform-
ing kidney tumor surgery, was moderate for a survey-based 
study, which mitigates this to some degree. Additionally, the 
study was completed before the EAU guidelines on VTEP 
were published. However, the results of our study may still be 
used as baseline evaluation to which future practice patterns 
can be compared in Scandinavia. It would be useful to repeat 
this study at defined intervals to test the incorporation of the 
EAU guidelines into clinical practice. Finally, this survey was 
intentionally restricted to the Nordic countries and, therefore, 
may not reflect the practice patterns elsewhere.
Conclusion
The study shows large differences in peri- and postoperative 
prophylactic treatment for VTE after renal surgery. This 
variation in care often does not match current guidelines 
from either the EAU or the Danish Society for Hematostasis 
and Thrombosis and should be reevaluated as these guide-
lines become more widely disseminated. Further studies are 
needed to be able to give evidence-based recommendations.
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Venous-thrombotic-embolic (VTE) prophylaxis survey for 
renal surgery
 1. Country in which you practice
 2. What form(s) of VTE prophylaxis do you use in patients 
with renal tumors before surgery (check all that apply)?
- None
- Aspirin
- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
 3. What form(s) of VTE prophylaxis do you use in patients 
undergoing renal surgery while they are in the hospital 
(check all that apply)?
- None
- Early ambulation
- Sequential compression device
- Compression stockings
- Aspirin
- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
 4. Do you use VTE prophylaxis in patients undergoing 
open nephrectomy after they leave the hospital?
Yes 
No – if no go to question 7




- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
 6. How long do you use VTE prophylaxis after patients 






 7. Do you use VTE prophylaxis in patients undergoing 
open partial nephrectomy after they leave the hospital?
Yes 
No – if no go to question 10




- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
 9. How long do you use VTE prophylaxis after patients 






 10. Do you use VTE prophylaxis in patients undergoing 
laparoscopic/ robot ass. nephrectomy after they leave 
the hospital?
Yes 
 No – if no go to question 13
11. If yes, what prophylaxis do you use (check all that apply)?
- Compression stockings
- Aspirin
- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
 12. How long do you use VTE prophylaxis after patients leave 






13. Do you use VTE prophylaxis in patients undergoing 
laparoscopic/ robot ass. partial nephrectomy after they 
leave the hospital?
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 Yes 
  No – if no go to question 16




- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
15. How long do you use VTE prophylaxis after patients 







16. Do you use VTE prophylaxis in patients undergoing 
laparoscopic/robotic thermal ablation of kidney tumors 
after they leave the hospital?
Yes 
No – if no go to question 19




- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
18. How long do you use VTE prophylaxis after patients 
leave the hospital for laparoscopic/robotic thermal abla-






19. Do you use VTE prophylaxis in patients undergoing 
percutaneous thermal ablation of kidney tumors after 
they leave the hospital?
Yes 
No – if no finished




- Direct-acting oral anticoagulants (dabigatran, apixa-
ban, rivaroxaban, edoxaban)
- Subcutaneous heparin
- Low molecular weight heparin
- Unfractionated heparin
- Other
21. How long do you use VTE prophylaxis after patients 
leave the hospital for percutaneous thermal ablation of 
kidney tumors?
- One week
- Two weeks
- Four weeks
- Six weeks
- Other
